A network meta-analysis on the efficacy of sixteen targeted drugs in combination with chemotherapy for treatment of advanced/metastatic colorectal cancer

Dan-Zeng Ba-Sang; Zi-Wen Long; Hao Teng; Xu-Peng Zhao; Jian Qiu; Ming-Shan Li

doi:10.18632/oncotarget.12994

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

A network meta-analysis on the efficacy of sixteen targeted drugs in combination with chemotherapy for treatment of advanced/metastatic colorectal cancer

Dan-Zeng Ba-Sang, Zi-Wen Long _, Hao Teng, Xu-Peng Zhao, Jian Qiu and Ming-Shan Li

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2016; 7:84468-84479. https://doi.org/10.18632/oncotarget.12994

Metrics: PDF 2212 views | HTML 2229 views | ?

Abstract

Dan-Zeng Ba-Sang1, Zi-Wen Long2,3, Hao Teng1, Xu-Peng Zhao1, Jian Qiu1, Ming-Shan Li1

1Department of Oncology, Shigatse People’s Hospital, Shigatse 857000, Tibet, P. R. China

2Department of Gastric Cancer and Soft-Tissue Sarcoma Surgery, Fudan university Shanghai Cancer Center, Shanghai 200032, P. R. China

3Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, P. R. China

Correspondence to:

Zi-Wen Long, email: [email protected]

Keywords: colorectal cancer, targeted drug, chemotherapy, randomized controlled trial, network meta-analysis

Received: May 06, 2016 Accepted: October 02, 2016 Published: October 31, 2016

ABSTRACT

Objective: A network meta-analysis was conducted comparing the short-term efficacies of 16 targeted drugs in combination with chemotherapy for treatment of advanced/metastatic colorectal cancer (CRC).

Results: Twenty-seven RCTs were ultimately incorporated into this network meta-analysis. Compared with chemotherapy alone, bevacizumab + chemotherapy, panitumumab + chemotherapy and conatumumab + chemotherapy had higher PR rate. Bevacizumab + chemotherapy, cetuximab + chemotherapy, panitumumab + chemotherapy, trebananib + chemotherapy and conatumumab + chemotherapy had higher ORR rate in comparison to chemotherapy alone. Furthermore, bevacizumab + chemotherapy had higher DCR rate than chemotherapy alone. The results of our cluster analysis showed that chemotherapy combined with bevacizumab, cetuximab, panitumumab, conatumumab, ganitumab, or brivanib + cetuximab had better efficacies for the treatment of advanced/metastatic CRC in comparison to chemotherapy alone.

Materials and Methods: Electronic databases were comprehensively searched for potential and related randomized controlled trials (RCTs). Direct and indirect evidence were incorporated for evaluation of stable disease (SD), progressive disease (PD), complete response (CR), partial response (PR), disease control rate (DCR) and overall response ratio (ORR) by calculating odds ratio (OR) and 95% confidence intervals (CI), and using the surface under the cumulative ranking curve (SUCRA).

Conclusions: These results indicated that bevacizumab + chemotherapy, panitumumab + chemotherapy, conatumumab + chemotherapy and brivanib + cetuximab + chemotherapy may have better efficacies for the treatment of advanced/metastatic CRC.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 12994

Publication Alerts

Research Papers:

A network meta-analysis on the efficacy of sixteen targeted drugs in combination with chemotherapy for treatment of advanced/metastatic colorectal cancer

Abstract